Filana Therapeutics, Inc. (FLNA) vs Nephros, Inc. (NEPH)
A side-by-side comparison of Filana Therapeutics, Inc. and Nephros, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FLNA
Filana Therapeutics, Inc.
$0.86HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
NEPH
Nephros, Inc.
$3.69HealthcareDelayed quote: Oct 6, 2026, 11:40 AM EDT
Total return — FLNA vs NEPH
growth of $100 · dividends reinvested · last 1yFLNA -57.6% (-57.6%/yr)NEPH -5.6% (-5.6%/yr)NEPH compounded faster over this window
FLNA NEPH
FLNA vs NEPH: by the numbers
- •FLNA is the larger company ($42M vs $40M market cap).
- •NEPH is profitable (8.38% net margin) while FLNA runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | FLNA | NEPH |
|---|---|---|
| P/E ratio | N/A | 23.25 |
| Forward P/E | N/A | 23.55 |
| P/S ratio | N/A | 1.93 |
| P/B ratio | 0.65 | 3.35 |
| EV / EBITDA | N/A | 20.53 |
Profitability
| Metric | FLNA | NEPH |
|---|---|---|
| Gross margin | 0.00% | 60.31% |
| Operating margin | 0.00% | 7.92% |
| Net margin | 0.00% | 8.38% |
| ROE | -66.47% | 14.51% |
| ROIC | -72.12% | 12.67% |
Growth (annualized)
| Metric | FLNA | NEPH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.99% |
| Total return CAGR (5Y) | N/A | -15.93% |
Frequently asked
- Is FLNA or NEPH more profitable?
- NEPH runs the higher net margin — FLNA at 0.00% versus NEPH at 8.38%.
Go deeper
Dig into the metrics
Nephros P/E ratioFilana Therapeutics ROENephros ROEFilana Therapeutics operating marginNephros operating marginFilana Therapeutics revenue growthNephros revenue growthFilana Therapeutics free cash flowNephros free cash flow
Filana Therapeutics & Nephros appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.